Skip to main content
Janssen seeks FDA approval for subcutaneous daratumumab formulation

Johnson & Johnson unit Janssen Biotech, a licensee of Genmab, has submitted to the FDA a marketing application to seek approval for a Darzalex, or daratumumab, formulation to be administered subcutaneously in patients with multiple myeloma. An intravenous formulation was previously approved by the FDA in November 2015.

Full Story: